Strategies for the targeted delivery of therapeutics for osteosarcoma

Expert Opinion on Drug Delivery

Volumn 6, Issue 12, 2009, Pages 1311-1321

  Hughes, Dennis Pm ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bisphosphonates; Inhalation chemotherapy; Intrapleural chemotherapy; Osteosarcoma; Samarium

Indexed keywords

BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; RAPAMYCIN; RUBITECAN; SAMARIUM; ZOLEDRONIC ACID;

BONE MARROW TOXICITY; CANCER SURVIVAL; CANCER THERAPY; CENTRAL VENOUS CATHETER; DRUG DELIVERY SYSTEM; HUMAN; LUNG METASTASIS; OSTEOSARCOMA; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; DRUG DELIVERY SYSTEMS; HUMANS; LIMB SALVAGE; OSTEOSARCOMA; SURVIVAL RATE;

EID: 71249107809     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903280422     Document Type: Review

References (82)

1. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009;125:229-234
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 2009;115(7):1531-1543
3. Herzog CE. Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 2005;27(4):215-218
4. Meyer WH, Malawer MM. Osteosarcoma. Clinical features and evolving surgical and chemotherapeutic strategies. Pediatr Clin North Am 1991;38(2):317-348
5. Longhi A, Errani C, De Paolis M, et al. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 2006;32(6):423-436
6. Anderson P, Kopp L, Anderson N, et al. Novel bone cancer drugs: Investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma). Expert Opin Investig Drugs 2008;17(11):1703-1715
7. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-a Report From the Children's Oncology Group. J Clin Oncol 2008;26(4):633-638
8. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: Presentation, treatment, and outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients. J Clin Oncol 2009;27(4):557-565
9. Goorin A, Andersen J. Experience with multiagent chemotherapy for osteosarcoma. Improved outcome. Clin Orthop 1991;270:22-28
10. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9(4):422-441
11. de Bari A, Krajbich JI, Langer F, et al. Modified Van Nes rotationplasty for osteosarcoma of the proximal tibia in children. J Bone Joint Surg Br 1990;72-B(6):1065-1069
12. Gottsauner-Wolf F, Kotz R, Knahr K, et al. Rotationplasty for limb salvage in the treatment of malignant tumors at the knee. A follow-up study of seventy patients. J Bone Joint Surg Am 1991;73(9):1365-1375
13. Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol 1998;9(8):893-899
14. Philip T, Iliescu C, Demaille MC, et al. High-dose methotrexate and HELP [Holoxan (ifosfamide), Eldesine (vindesine), platinum] - doxorubicin in non-metastatic osteosarcoma of the extremity: A French multicentre pilot study. Ann Oncol 1999;10(9):1065-1071
15. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group Trial. J Clin Oncol 2002;20(2):426-433
16. Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: Recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 2003;14(7):1126-1134
17. Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005;23(34):8845-8852
18. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma: Intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 1983;51(3):402-407
19. Jaffe N, Prudich J, Knapp J, et al. Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate. J Clin Oncol 1983;1(7):428-431
20. Jaffe N, Raymond AK, Ayala A, et al. Effect of cumulative courses of intraarterial cis-diamminedichloroplatin-II on the primary tumor in osteosarcoma. Cancer 1989;63(1):63-67
21. Bacci G, Picci P, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. The Istituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 1990;65(11):2539-2553
22. Winkler K, Bielack S, Delling G, et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic doxorubicin, high-dose methotrexate, and ifosfamide on histologic tumor response in osteosarcoma (study COSS-86). Cancer 1990;66(8):1703-1710
23. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23(3):559-568
24. Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 2006;8(4):310-315
25. Misdorp W. Skeletal osteosarcoma. Animal model: Canine osteosarcoma. Am J Pathol 1980;98(1):285-288
26. Brodey R. The use of naturally occurring cancer in domestic animals for research into human cancer: General considerations and a review of canine skeletal osteosarcoma. Yale J Biol Med 1979;52(4):345-361
27. Gagnadoux F, Hureaux J, Vecellio L, et al. Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv 2008;21(1):61-70
28. Gordon N, Koshkina NV, Jia SF, et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007;13(15 Pt 1):4503-4510
29. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005;116(3):458-463
30. Rodriguez CO, Crabbs TA, Cannan VA, et al. Aerosol gemcitabine: In vivo antitumor activity and preclinical safety assessment in osteosarcoma bearing dogs. Journal of aerosol medicine and pulmonary drug delivery 2009 [In press]
31. Gagnadoux F, Leblond V, Vecellio L, et al. Gemcitabine aerosol: In vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons. Cancer Chemother Pharmacol 2006;58(2):237-244
32. Verschraegen CF, Gilbert BE, Loyer E, et al. Clinical evaluation of the delivery and safety of aerosolized liposomal 9-Nitro-20(S)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 2004;10(7):2319-2326
33. Gill GN, Kawamoto T, Cochet C, et al. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984;259(12):7755-7760
34. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44(3):1002-1007
35. Hudziak RM, Lewis GD, Winget M, et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9(3):1165-1172
36. Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16(9):3053-3060
37. Cheung NK, Kushner BH, Yeh SJ, Larson SM. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: A phase II study. Prog Clin Biol Res 1994;385:319-328
38. Cohen S, Ushiro H, Stoscheck C, Chinkers M. A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 1982;257(3):1523-1531
39. Shupnik M, Antoniades H, Tashjian A. Platelet-derived growth factor increases prostaglandin production and decreases epidermal growth factor receptors in human osteosarcoma cells. Life Sci 1982;30(4):347-353
40. Hirata Y, Uchihashi M, Nakashima H, et al. Specific receptors for epidermal growth factor in human bone tumour cells and its effect on synthesis of prostaglandin E2 by cultured osteosarcoma cell line. Acta Endocrinol (Copenh) 1984;107(1):125-130
41. Fellenberg J, Krauthoff A, Pollandt K, et al. Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in laser-microdissected paraffin-embedded tissue. Lab Invest 2004;84(1):113-121
42. Ferrari S, Bertoni F, Zanella L, et al. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 2004;100(9):1936-1942
43. Gorlick R, Huvos AG, Heller G, et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999;17(9):2781-2788
44. Zhou H, Randall R, Brothman A, et al. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 2003;25(1):27-32
45. Akatsuka T, Wada T, Kokai Y, et al. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 2002;94(5):1397-1404
46. Akatsuka T, Wada T, Kokai Y, et al. Loss of ErbB2 expression in pulmonary metastatic lesions in osteosarcoma. Oncology 2001;60(4):361-366
47. Anninga J, van de Vijver M, Cleton-Jansen A, et al. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 2004;40(7):963-970
48. Hughes DPM, Thomas DG, Giordano TJ, et al. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 2004;64(6):2047-2053
49. Hughes DPM, Thomas DG, Giordano TJ, et al. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 Inhibition. Pediatric Blood Cancer 2006;46(5):614-623
50. Witlox M, Van Beusechem V, Grill J, et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med 2002;4(5):510-516
51. Wen YH, Koeppen H, Garcia R, et al. Epidermal growth factor receptor in osteosarcoma: Expression and mutational analysis. Hum Pathol 2007;38(8):1184-1191
52. Gordon EM, Chan MT, Geraldino N, et al. Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. Int J Oncol 2007;30(6):1297-1307
53. Gordon EM, Cornelio GH, Lorenzo CC, et al. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. Int J Oncol 2004;24(1):177-185
54. Gordon EM, Lopez FF, Cornelio GH, et al. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: Three-year clinical experience. Int J Oncol 2006;29(5):1053-1064
55. Chawla SP, Chua VS, Fernandez L, et al. Phase I/II and Phase II studies of targeted gene delivery in vivo: Intravenous Rexin-G for chemotherapy- resistant sarcoma and osteosarcoma. Mol Ther 2009;17:1651-1657
56. Dass CR, Friedhuber AM, Khachigian LM, et al. Biocompatible chitosan-DNAzyme nanoparticle exhibits enhanced biological activity. J Microencapsul 2008;25(6):421-425
57. Tan ML, Choong PF, Dass CR. Osteosarcoma: Conventional treatment vs. gene therapy. Cancer Biol Ther 2009;8(2):106-117
58. Tan ML, Choong PF, Dass CR. Cancer, chitosan nanoparticles and catalytic nucleic acids. J Pharm Pharmacol 2009;61(1):3-12
59. Dass CR, Khachigian LM, Choong PFM. c-Jun knockdown sensitizes osteosarcoma to doxorubicin. Mol Cancer Ther 2008;7(7):1909-1912
60. Subramanian G, McAfee JG, Blair RJ, et al. Technetium-99m-methylene diphosphonate-a superior agent for skeletal imaging: Comparison with other technetium complexes. J Nucl Med 1975;16(8):744-755
61. Castronovo FP Jr, Callahan RJ. New bone scanning agent: 99mTc-Labeled 1-Hydroxy-Ethylidene-1, 1-Disodium phosphonate. J Nucl Med 1972;13(11):823-827
62. Davis MA, Jones AL. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med 1976;6(1):19-31
63. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Eur J Cancer 1991;27(9):1084-1086
64. Moe L, Boysen M, Aas M, et al. Maxillectomy and targeted radionuclide therapy with 153Sm-EDTMP in a recurrent canine osteosarcoma. J Small Anim Pract 1996;37(5):241-246
65. Lattimer JC, Corwin LA Jr, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium- 153-EDTMP. J Nucl Med 1990;31(8):1316-1325
66. Milner RJ, Dormehl I, Louw WK, Croft S. Targeted radiotherapy with Sm-153-EDTMP in nine cases of canine primary bone tumours. J S Afr Vet Assoc 1998;69(1):12-17
67. Anderson PM, Wiseman GA, Erlandson L, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 2005;11(19):6895-6900
68. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 2002;20(1):189-196
69. Anderson P, Nunez R. Samarium lexidronam (153Sm-EDTMP): Skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther 2007;7(11):1517-1527
70. Mahajan A, Woo SY, Kornguth DG, et al. Multimodality treatment of osteosarcoma: Radiation in a high-risk cohort. Pediatr Blood Cancer 2008;50(5):976-982
71. Heron DE, Brufsky A, Beriwal S, Kurman M. Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Ann Oncol 2008;19(9):1639-1643
72. MacLean C, Newberry S, Maglione M, et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148(3):197-213
73. Iguchi T, Miyakawa Y, Saito K, et al. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol 2007;31(2):285-291
74. Ory B, Moriceau G, Trichet V, et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008;12(3):928-941
75. Baczyk M, Baczyk E, Sowinski J. Preliminary results of combined application of radioisotopes and biphosphonates in the management of pain associated with osteoblastic-osteolytic bone metastases of breast cancer. Ortop Traumatol Rehabil 2003;5(2):234-237
76. Perry CM, Figgitt DP. Zoledronic acid: A review of its use in patients with advanced cancer. Drugs 2004;64(11):1197-1211
77. Wellington K, Goa KL. Zoledronic acid: A review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 2003;63(4):417-437 (Pubitemid 36259531)
78. Ashton JA, Farese JP, Milner RJ, et al. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 2005;66(5):885-891
79. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12(5):459-465
80. Labrinidis A, Hay S, Liapis V, et al. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse Model. Clin Cancer Res 2009;15(10):3451-3461
81. Tomlin JL, Sturgeon C, Pead MJ, Muir P. Use of the bisphosphonate drug alendronate for palliative management of osteosarcoma in two dogs. Vet Rec 2000;147(5):129-132
82. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42(11):1228-1236